Page last updated: 2024-12-09

2-(1-naphthalenyl)-N-(2-phenyl-1,3-benzoxazol-5-yl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 2-(1-Naphthalenyl)-N-(2-phenyl-1,3-benzoxazol-5-yl)acetamide: A Promising Molecule

**2-(1-Naphthalenyl)-N-(2-phenyl-1,3-benzoxazol-5-yl)acetamide**, often shortened to **compound A** or **NAP-BOZ**, is an organic molecule with potential applications in various research fields. Its importance stems from its unique structure and demonstrated biological activities, making it a promising candidate for:

**1. Anti-cancer research:**

* **Potential as a cytotoxic agent:** Preliminary studies indicate compound A exhibits significant cytotoxicity against various cancer cell lines, including breast, lung, and colon cancer cells. This suggests it might act as a potent anti-cancer drug candidate.
* **Specific targeting:** Further research is needed to understand its mechanism of action and explore its selectivity towards specific cancer cells, potentially leading to more targeted and effective therapies.

**2. Pharmacology and drug development:**

* **Understanding the relationship between structure and activity:** Compound A's structure, combining a naphthalene moiety with a benzoxazole ring, allows for systematic modifications to investigate the impact on its biological activity. This approach can help develop new and improved drug candidates by tailoring their properties.
* **Exploring other therapeutic applications:** The benzoxazole ring is known to exhibit diverse biological activities, including anti-inflammatory, antimicrobial, and antioxidant properties. Compound A's unique structure might offer potential for exploring other therapeutic applications beyond cancer treatment.

**3. Materials science and nanotechnology:**

* **Luminescence properties:** The presence of aromatic rings like naphthalene and benzoxazole can lead to interesting luminescence properties, potentially allowing compound A to be used in various optical applications, such as organic light-emitting diodes (OLEDs).
* **Self-assembly and supramolecular chemistry:** Understanding how compound A interacts with other molecules could lead to novel self-assembled materials with unique properties for various applications, including drug delivery and sensing.

**4. Chemical synthesis and organic chemistry:**

* **Developing new synthetic methods:** The synthesis of compound A provides valuable information for developing new and efficient methods for synthesizing similar complex molecules with desired properties.
* **Understanding the reactivity and stability:** Studying compound A's chemical behavior can contribute to our understanding of the reactivity and stability of other molecules with similar functional groups, leading to improved design and synthesis of new compounds.

**It's crucial to remember that compound A is still under investigation and more research is needed to fully understand its potential benefits and applications.** The information provided above is based on current research and might be subject to change as further studies are conducted.

Cross-References

ID SourceID
PubMed CID1304440
CHEMBL ID1399460
CHEBI ID111366

Synonyms (9)

Synonym
2-(1-naphthyl)-n-(2-phenyl-1,3-benzoxazol-5-yl)acetamide
MLS000535614
smr000143050
CHEBI:111366
2-naphthalen-1-yl-n-(2-phenyl-1,3-benzoxazol-5-yl)acetamide
HMS2352I07
CHEMBL1399460
Q27191079
2-(1-naphthalenyl)-n-(2-phenyl-1,3-benzoxazol-5-yl)acetamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,3-oxazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency63.09570.100020.879379.4328AID588453; AID588456
BRCA1Homo sapiens (human)Potency11.22020.89137.722525.1189AID624202
ClpPBacillus subtilisPotency19.95261.995322.673039.8107AID651965
phosphopantetheinyl transferaseBacillus subtilisPotency14.12540.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency20.59620.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency32.64270.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.51740.00419.984825.9290AID504444
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency95.28340.425612.059128.1838AID504891
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency112.20200.050127.073689.1251AID588590
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency31.62280.00419.962528.1838AID2675
neuropeptide S receptor isoform AHomo sapiens (human)Potency25.11890.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]